Further research has indicated the importance of the Notch-Jagged1 signaling pathway in prognosticating outcomes for patients with advanced CRC treated with bevacizumab; high marker expression correlates with early disease progression during treatment (65). This evidence concerns the gene JAG1 and colorectal carcinoma.